Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Completed · Phase 3 · NCT05067634
Conditions: Partial Epilepsy
At a glance
- Research payments reported, 2025
- $735,957
- U.S. investigators named
- 18
- Sites paid
- 18
- Planned or actual enrollment
- 154
About the trial
- Sponsor
- SK Life Science, Inc.
- Tested
- Xcopri (drug)
- Dates
- Started 2022-01-10; completion 2026-10-02
- Results posted
- Not yet
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sk Life Science, Inc. reported $735,957 in research payments for this study in 2025 (206 payments).
Products named: Xcopri
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Angus Wilfong, MD Child Neurology · Phoenix, AZ
- William B. Gallentine, MD Neurology · Palo Alto, CA
- Jennifer E. Madan Cohen, MD Child Neurology · Hartford, CT
- Julio R. Flamini, M.D. Neurology · Atlanta, GA
- Yong D. Park, MD Child Neurology · Augusta, GA
- Robin D. Cook, M.D. General Practice · Marquette, MI
- Robin J. Cook, M.D., PH.D. Child Neurology · Grand Rapids, MI
- Lily C. Wong-kisiel, M.D. Neurology · Rochester, MN
- Muhammad S. Zafar, M.D. Neurology · Durham, NC
- Rajeshwari Mahalingam Neurology · New Brunswick, NJ
- Eric B. Segal, M.D. Child Neurology · N White Plains, NY
- Steven Wolf, MD Neurology · New York, NY
- Michael H. Kohrman, MD Child Neurology · Akron, OH
- Deepak K. Lachhwani, MD Child Neurology · Cleveland, OH
- Sudha K. Kessler, MD Child Neurology · Philadelphia, PA
- James Wheless, MD Child Neurology · Memphis, TN
- Karen C. Keough, MD Neurology · Austin, TX
- Steven A. Phillips, MD Pediatrics · Tacoma, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Epilepsy & Neurophysiology $255,537
- Duke University $157,149
- Tacoma General Allenmore Hospital, WA $59,427
- Cleveland Clinic, OH $57,426
- Le Bonheur Children's Hospital Foundation $41,637
- Connecticut Childrens Medical Center, CT $31,892
- Phoenix Children's Hospital, AZ $28,050
- Clinical Integrative Research Center of Atlanta $19,009
- Mid-Atlantic Epilepsy & Sleep Center $17,390
- Spectrum Health System $15,716
- Child Neurology Consultants of Austin $14,826
- Pediatrix Management Services Inc $10,950
- Stanford University $10,029
- Augusta University Research Institute Inc. $5,456
- Mayo Clinic Rochester $5,425
- Akron Children's Hospital, OH $2,550
- Children's Hospital of Philadelphia, PA $2,490
- New York Medical College Office of Research $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.